Back

Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis

29 August 2026 (16:35 - 16:45)
Organised by: Logo
Congress Presentation Part of: Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes Renal Failure and Cardiovascular Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Sapna Rao

RTI International, Durham (United States of America)

4 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on left ventricular mass in patients with kidney failure receiving maintenance hemodialysis: Primary results from the DAPA-HD trial
Associate Professor T. Zelniker (Vienna, AT)
Abstract Slides
Presentation thumbnail
Nanoformulated omega-3-rich linseed oil reverses ex vivo the phenotype of monocytes of hemodialysis patients from a pro into an anti-inflammatory one with attenuated ROS formation and cell activation
Doctor G. Lima (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
Analysis of the effect of specific therapy on exercise capacity in patients with anderson-fabry disease
Doctor A. Cuomo (Naples, IT)
Abstract Slides
Presentation thumbnail
Omega-3 fatty acid supplementation and major cardiovascular events in maintenance haemodialysis: Systematic review and meta-analysis including PISCES
Doctor M. Egaimi (Ras al Khaimah, AE)
Abstract Slides

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes

The Event

Event poster

ESC Congress 2026

29 August 2026 16:35 CET
You may be interested in
thumbnail
Congress Presentation
Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials
19 May 2025
thumbnail
Congress Presentation
Effectiveness and safety of sacubitril/valsartan in patients with stage 4 chronic kidney disease in a real-world population
29 June 2021
thumbnail
Congress Session
Treating heart failure with diabetes and renal disease
12 May 2024
thumbnail
ESC Journals
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources